The Oncomine Dx Express Test covers all clinically relevant biomarkers in NSCLC and the majority in other solid tumors.

The European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT)¹

Tier I. Ready for routine use
Alteration-drug match is associated with improved outcome in clinical trial

Tier II. Investigational
Alteration-drug match is associated with anti-tumor activity, but magnitude of benefit is unknown

Tiers III and IV. Hypothetical target
III. Alteration-drug match is suspected to improve outcome based on clinical trial data in other tumor types; IV. Pre-clinical evidence of actionability

Tier V. Combination development
Alteration-drug match is associated with objective response, but without clinical benefit

Tier X. Lack of evidence
Lack of evidence for actionability

The Oncomine Dx Express Test gene targets per professional medical guidelines,²⁻³ including ESCAT tier I for clinically relevant biomarkers and approved therapies.

* BRCA1/2 and MSI-H are not covered by the Oncomine Dx Express Test.

For In Vitro Diagnostic Use. CE-IVD according to IVDD. Not available in all countries, including the United States. © 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. EXT1648 0722